The Most Popular Peptides for Recovery & Performance
Learn about the peptides generating the most attention across recovery and performance, why healthcare organizations are watching them, and what current research says about each.
As interest in recovery and performance services grows, organizations are evaluating whether peptide-related therapies fit within the broader longevity, metabolic health, and wellness offerings.
Some peptide drugs have established FDA-approved uses for specific medical conditions while others are attracting attention for their potential roles in muscle recovery, exercise performance, sleep, and body composition. The FDA’s ongoing review of nominated peptide bulk drug substances has increased attention to the category.
This article covers the most popular peptides for recovery and performance, selected based on a combination of clinical adoption, research activity, patient interest, and market momentum. For each peptide, we'll explain what it is, why it's being studied, how it's commonly discussed in recovery-focused care, and its current regulatory status.
This article is for general informational purposes; it does not recommend any peptide, establish that a peptide is safe or effective for a particular use or constitute medical or legal advice. Compounding and prescribing must comply with applicable federal and state law and be based on an individualized clinical assessment.
What Are Recovery and Performance Peptides?
Peptides are short chains of amino acids that naturally occur throughout the body and help regulate processes such as hormone signaling, metabolism, immune function, tissue repair, and cellular communication.
In recovery and performance medicine, published research has explored peptides in relation to tissue repair, musculoskeletal health, metabolic health, and related physiological processes. Depending on the peptide, studies have investigated potential roles in recovery, resilience, and physical performance.
Evidence varies widely by peptide. Some peptide drugs have established FDA-approved uses for specific conditions, while many recovery or performance related uses discussed below remain investigational and may be supported primarily by preclinical or otherwise limited evidence.
Why Are Peptides Receiving So Much Attention?
According to Google Ads Keyword Planner, searches for "peptide" increased by roughly 398% YoY between June 2025 and July 2026 with over 600K average monthly searches (Google Ads Keyword Planner).
Peptides have moved into conversations across primary care, metabolic health, men's and women's health, sleep medicine, performance and recovery, and aesthetics.
Patients are becoming more familiar with ‘peptide therapy’. At the same time, the FDA is evaluating certain bulk drug substances nominated for use in compounding, bringing additional visibility to the category.
What Does "Compounded" Mean, and Why Does It Matter Here?
503A compounding pharmacies prepare patient-specific medications pursuant to a valid prescription for an individually identified patient. When bulk drug substances are used, including the 503A Bulks List and FDA’s Interim Category 1 policy for certain nominated substances under evaluation. For the recovery and performance uses discussed in this article, it’s important to understand that the peptides described below are not FDA-approved for those purposes, and any compounding must comply with applicable federal and state requirements.
Certain peptide bulk drug substances currently listed in FDA’s Category 1 may fall within FDA’s interim enforcement policy for compounding , provided all applicable conditions are met. Category 1 status does not constitute FDA approval or formal inclusion on the 503A Bulks List, which requires separate rulemaking.
That's why you'll see a regulatory status for each peptide below: it describes where that substance currently sits within the FDA's compounding framework — not whether the peptide has been proven safe or effective for any particular use.
The Most Popular Peptides for Recovery & Performance
Recovery and performance programs include peptides with varying levels of scientific evidence and clinical use. Some have a more established role in hormone related therapies and are currently listed in FDA’s Category 1 under the agency’s interim enforcement policy for certain bulk drug substances under review.
Others are being investigated for potential roles in muscle recovery, exercise physiology, metabolism, sleep, and cognitive performance, although the strength of evidence varies and many uses remain investigational.
The substances below are organized by their regulatory pathway relevant to this discussion: a previously approved drug component pathway under Section 503A, substances that received favorable non-binding Pharmacy Compounding Advisory Committee (PCAC) recommendations but have not been added to the 503A Bulks List, and substances the FDA has announced for future PCAC consideration.
Recovery and Performance Peptides Currently Eligible for 503A Compounding
Sermorelin
Sermorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the anterior pituitary to release the body’s own growth hormone rather than replacing growth hormone directly. It is discussed in hormone optimization programs because of its role in the body’s natural growth hormone pathway.
The FDA previously approved sermorelin acetate products for specific diagnostic and pediatric indications. While interest has expanded into recovery and performance medicine, it is not currently FDA approved for these uses and evidence supporting such applications continues to evolve.
Regulatory status: Sermorelin acetate qualifies for 503A compounding as a component of a previously FDA approved drug (Geref). A compounder relying on the previously FDA approved drug component pathway under section 503A must satisfy all applicable federal and state requirements.
PCAC Recommends (Advisory Only) : Not Current Compounding Authorization
BPC-157
BPC-157 is a synthetic peptide that has become one of the most widely discussed peptides in recovery and performance. It has been studied for gastrointestinal health. Separate preclinical research has explored its potential role in tendon, ligament, and muscle repair.
Most published evidence comes from laboratory and animal studies, and human clinical data remain limited.
Regulatory status: In July 2026, PCAC voted to recommend BPC-157 related bulk drug substances for inclusion on the 503A Bulks List. The recommendation is non-binding. The FDA has not added BPC-157 to the 503A Bulks List and the PCAC vote does not itself authorize compounding.
MOTS-c
MOTS-c is a mitochondrial-derived peptide studied in metabolism and exercise physiology. Published research has explored its potential role in obesity, insulin sensitivity, glucose metabolism, and exercise performance.
Regulatory status: In July 2026, PCAC voted to recommend MOTS-c related bulk drug substances for inclusion on the 503A Bulks List. The recommendation is non-binding. The FDA has not added MOTS-c to the 503A Bulks List and the PCAC vote does not itself authorize compounding.
Semax
Semax has gained attention in cognitive research because of its potential effects on learning, memory and synaptic function. It has been used outside the United States for certain neurological applications and is discussed in research involving neurotrophic signaling and cognition.
Published research includes laboratory and animal studies examining its effects on neurotrophic signaling outside the United States. While its international history contributes to its popularity, evidence supporting recovery or performance applications remains limited in the U.S. and has not been established through well-controlled clinical trials.
Regulatory status: In July 2026, PCAC voted to recommend Semax related bulk drug substances for inclusion on the 503A Bulks List. The recommendation is non-binding. The FDA has not added Semax to the 503A Bulks List and the PCAC vote does not itself authorize compounding.
KPV
KPV is a small peptide fragment derived from alpha-melanocyte-stimulating hormone (alpha-MSH). The FDA’s July 2026 PCAC review evaluated KPV related bulk substances for wound healing and inflammatory conditions. Interest in recovery settings is based largely on mechanistic and preclinical research and does not establish clinical efficacy.
Most published evidence remains preclinical, and while KPV continues to generate research interest, additional human studies are needed to better understand its potential role in recovery and performance.
Regulatory status: In July 2026, PCAC voted to recommend KPV related bulk drug substances for inclusion on the 503A Bulks List. The recommendation is non-binding. The FDA has not added KPV to the 503A Bulks List and the PCAC vote does not itself authorize compounding. See our blog on the most popular longevity and aesthetic peptides
Peptides and Related Compounds Waiting to Be Reviewed By PCAC in 2027
The FDA has announced that it intends to hold a PCAC meeting before the end of February 2027 to discuss the substances below, which have been discussed in the longevity, recovery, regenerative medicine and aesthetic care circles. As of this review, the FDA has not posted a final meeting date. Being scheduled or identified for future advisory committee consideration does not establish compounding eligibility, safety, effectiveness or likely inclusion on the 503A Bulks List.
GHK-Cu
GHK-Cu is a naturally occurring copper-binding peptide studied primarily in topical, dermatologic, wound healing and laboratory contexts. It’s best known for research related to collagen production, tissue repair, wound healing, and hair health. Although it's most commonly associated with aesthetic medicine and skincare, it has been studied in relation to collagen production, wound healing, and tissue repair. Evidence and regulatory status vary by route of administration.
Regulatory status: GHK-Cu, except for injectable routes of administration, appears in FDA’s current Category 1 list and is within the scope of FDA’s interim enforcement policy only when all guidance conditions are met. Injectable GHK-Cu is excluded from Category 1. FDA has announced it intends to consult PCAC about GHK-Cu before the end of February 2027.
Cathelicidin (LL-37)
Cathelicidin (LL-37) is a naturally occurring antimicrobial peptide involved in innate immune response. It is being studied as a host-defense peptide involved in innate immunity. Research has examined wound healing, inflammation, host defense and immune regulation, but most proposed clinical uses remain investigational. Most published research remains preclinical, and additional human studies are needed to better understand its clinical role.
Regulatory status: The FDA has announced that it intends to present Cathelicidin (LL-37) to PCAC before the end of February 2027 for possible inclusion on the 503A Bulks List. Future PCAC review does not itself permit compounding.
Dihexa Acetate
Dihexa acetate is a synthetic peptidomimetic derived from angiotensin IV. It has been investigated in preclinical research for potential effects on synaptic plasticity and cognitive function, but published human clinical evidence remains extremely limited.
Regulatory status: The FDA has announced that it intends to present it to PCAC before the end of February 2027 for possible inclusion on the 503A Bulks List. Future PCAC review does not itself permit compounding.
Pegylated Mechano Growth Factor (PEG-MGF)
PEG-MGF is a synthetic, PEGylated analog of mechano growth factor (MGF), a naturally occurring splice variant of insulin-like growth factor-1 (IGF-1) that is produced in skeletal muscle following mechanical stress or injury. Researchers are investigating its potential role in muscle repair, regeneration and adaptation to exercise, although published evidence remains limited to laboratory and animal studies. Human clinical trials are sparse.
Regulatory status: The FDA has announced that it intends to present it to PCAC before the end of February 2027 for possible inclusion on the 503A Bulks List. Future PCAC review does not itself permit compounding.
Melanotan II
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide that regulates skin pigmentation. It is primarily known for increasing melanin production and has been studied for its effects on pigmentation. Published evidence supporting human use remains limited.
Published human safety data remains limited, and Melanotan II is not FDA-approved.
Regulatory status: The FDA has announced that it intends to present it to PCAC before the end of February 2027 for possible inclusion on the 503A Bulks List. Future PCAC review does not itself permit compounding.
PCAC Consideration or Recommendation is not FDA Approval or Compounding Authorization
The regulatory landscape for peptide therapy continues to evolve.
PCAC provides non-binding advice to the FDA, PCAC consideration or a favorable vote does not add a substance to the 503A Bulks List and does not establish that a particular compounded drug may be lawfully prepared, prescribed, dispensed or advertised.
Formal inclusion requires FDA rulemaking. Even when a substance is on the Bulks List or within Category 1 enforcement policy, all other section 503A conditions and applicable state laws remain in force.
Compounded drugs are not FDA approved and the FDA does not review compounded drugs for safety, efficacy or quality.
Interested organizations should continue monitoring FDA guidance as peptide policy evolves.
Build a Clinically Compliant Peptide Therapy Program In Just Days with OpenLoop®
Whether additional peptides move through FDA review or remain under evaluation, organizations face the same challenge: preparing for growing patient interest while building clinically compliant programs that can adapt as the regulatory landscape changes.
That means thinking beyond any single peptide. Successful peptide therapy programs require clinical protocols, provider networks, pharmacy partnerships, patient workflows, and technology designed to support safe, outcome-driven care at scale.
OpenLoop has already built that infrastructure. Our virtual care platform supports more than 500,000 patient visits each month and helps healthcare organizations launch and scale clinically compliant programs, including peptide therapy— whether you're expanding an existing longevity offering or exploring peptide therapy for the first time.
Learn more about how to offer a peptide therapy program for your business.
*This content is intended for general informational purposes only and should not be construed as legal advice. For guidance on your specific situation, please consult a licensed attorney.